Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study

Brief description of study

The purpose of this study is to allow continued use of nilotinib in patients who are on nilotinib treatment in a Novartis-sponsored, Oncology Clinical Development & Medical Affairs (CD&MA) study and are benefiting from the treatment as judged by the investigator

Clinical Study Identifier: NCT01735955

Start Over

Sorry. There are no research sites conducting this study in the radius provided. ( View all Sites )

If you would like to be informed of other studies that may be of interest to you, you may sign up for CenterWatch.com's Patient Notification Service.

Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study

Brief description of study

Volunteer Sign-up